Abstract: Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Abstract: A bioFET cell for measuring a time dependent characteristic of an analyte bearing fluid includes a source, a drain, a semiconductive single wall carbon nanotube network layer extending between the source and drain electrodes and electrically coupled there between, a gate insulatively spaced from and disposed over and extending between the source and drain electrodes, a layer of at least one selected antibody disposed on and linked to the polymer layer to functionalize the semiconductive single wall carbon nanotube network layer to a selected target biomarker corresponding to the at least one selected antibody so that electron transport into the semiconductive single wall carbon nanotube network layer is facilitated, where the source, drain and gate electrodes with the carbon nanotube network layer form a defined channel through which the analyte bearing fluid may flow, and a high impedance source follower amplifier coupled to the source electrode.

Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of snaking nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.

Abstract: Example methods of quantifying known and unknown risks of an adverse drug event in an individual based on various factors are disclosed. In some embodiments, factors include known drug-drug interactions and unknown phenotypes of cytochromes. Quantification may be based on severity of the adverse drug event/and or probability of occurrence in some embodiments. Example methods of displaying the quantified risk are also disclosed. In one embodiment, the risk of individuals is aggregated to display the risk of a population.

Abstract: This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound.

Abstract: The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.

Abstract: Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IV A, MPS-VI, and MPS VII. In one aspect, the invention provides methods for assaying one or more enzymes associated with a lysosomal storage disease. In a first embodiment, the method includes: (a) contacting a sample with a first solution to provide a solution comprising one or more lysosomal enzymes; (b) contacting the one or more lysosomal enzymes in solution with an enzyme substrate for each lysosomal enzyme to be analyzed and incubating the substrates with the enzymes for a time sufficient to provide a solution comprising an enzyme product for each lysosomal enzyme present in the sample.

Abstract: A feedback control mechanism for a fermentation of yeast cells to make recombinant proteins uses a respiratory quotient measurement which adjusts the levels of oxygenation and/or fermentable sugar feed. The feedback control mechanism permits well controlled cultures that produce good amounts of product while avoiding toxic accumulation of ethanol. Additionally, recombinant proteins so produced have excellent qualitative properties, such as excellent homogeneity and proper inter-subunit assembly.

Abstract: Systems and methods are described for isolation, separation and detection of a molecular species using a low resource device for processing of samples. Methods include isolation, separation and detection of whole cells as well as biomolecules including viruses, proteins, nucleic acids, carbohydrates and lipids.

Abstract: A mass calibration kit and a calibration method for a low-mass area of a high-resolution mass spectrometer in negative ion mode. The mass calibration kit comprises semiconductor nanometer material suspension, a free fatty acid standard solution and a MALDI sample target cleaning liquid. The mass calibration method comprises: adjusting a voltage difference between a sample target of the mass spectrometer and a slit to be 20 V; dripping the semiconductor nanometer material suspension on the surface of the sample target till a solvent is completely volatilized and dried; dripping the free fatty acid standard solution on the surface of a semiconductor nanometer material till the solvent is completely volatilized and dried; and putting the sample target in the mass spectrometer for mass calibration, wherein calibration coefficients obtained after the instrument calibration can be used for correcting a sample mass spectrometric detection result.

Abstract: Provided herein are devices and methods for the micro-isolation of biological cellular material. A micro-isolation device described can comprise a photomask that protects regions of interest against DNA-destroying illumination. The micro-isolation device can further comprise photosensitive material defining access wells following illumination and subsequent developing of the photosensitive material. The micro-isolation device can further comprise a chambered microfluidic device comprising channels providing access to wells defined in photosensitive material. The micro-isolation device can comprise a chambered microfluidic device without access wells defined in photosensitive material where valves control the flow of gases or liquids through the channels of the microfluidic device.

Abstract: The invention is directed to a novel method for measuring contraction characteristics of engineered heart tissue constructs (16) which is based on the mechanical coupling of the construct (16) to a support element (8) which comprises or is mechanically coupled to a piezoelectric element (10). An apparatus (1) for carrying out the method of the invention is also provided.

Abstract: A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide/nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.

Abstract: The present disclosure relates to particular nucleotide sequences comprising of at least one stem and/or loop structure and which optionally bind fluorescent labels, for example DFHBI and a process for obtaining said sequences. The present disclosure also provides nucleic acid sensor for cAMP comprising reporter domain, communication module and target recognition domain. Further, the present disclosure provides for ratiometric sensors 10 for quantifying cAMP using the nucleic sensors of the instant invention. The instant disclosure further provides method for obtaining the sensors, method for detecting and measuring small molecules, such as cAMP using the sensors of the instant disclosure and kits thereof.

Abstract: A quantum dot includes: a core including at least one first positive ion precursor and at least one negative ion precursor; a shell including at least one second positive ion precursor and at least one negative ion precursor and wrapping the core; and a ligand formed on a surface of the shell, wherein the first positive ion precursor is an n-period element and the second positive ion precursor is an (n-1)-period element, where n is an integer of 3 to 6.

Abstract: This disclosure provides a system for detecting rare cells. The system includes a substrate, extensions extending outwardly from the substrate and arranged about a center axis of the substrate to define a channel enabling the fluid to move radially from the center axis to an outer edge of the substrate, and a functionalized graphene oxide disposed on the extension. This disclosure also provides a method for detecting rare cells using the system of this disclosure. The method includes the steps of introducing a sample of fluid containing the rare cells into the inlet of the system such that the sample of fluid flows radially from the inlet toward the outer edge of the substrate and capturing the rare cells as the rare cells interact with the functionalized graphene oxide disposed on the extensions.

Abstract: An integrated sample purification system includes a housing, a sample container rack, a filter holder, and a cylindrical magnet. The sample container rack and the filter device holder are disposed in the housing. The sample container rack is configured to hold one or more sample containers, the filter device holder is configured to hold one or more filter devices. The cylindrical magnet is adjacent to and external to the sample container rack, and is rotated about a central, longitudinal axis of the magnet by an electric motor disposed in the housing to lyse cells. Molecules of interest in the lysed cells are purified using filters that bind specifically to the molecules of interest. The system is readily amenable to automation and rapid purification and analysis of molecules of interest, such as nucleic acids and proteins.

Abstract: Various embodiments are described herein for controlling the self-assembly process of paramagnetic particles and the final particle cluster size using a liquid-liquid interface. The number of paramagnetic particles within a particle cluster and coating at the liquid-liquid interface may be controlled by systematically varying the strength of an applied magnetic field gradient and the interfacial tension of the liquid-liquid interface.

Abstract: The present invention provides a method for inducing differentiation of pluripotent stem cells into neural precursor cells, comprising culturing the pluripotent stem cells in the presence of a small molecule BMP inhibitor, and induced neural precursor cells prepared by this method.

Abstract: A system includes a microfluidic device configured to isolate one or more particles from a mixture, a flow rate matching device configured to match flow rate of the microfluidic device with flow rate of an electrical measurement device configured to measure an electrical property of the isolated particles, and an electrical measurement device configured to measure an electrical property of the isolated particles.

Abstract: A method and system analyzes multi-resolution medical images. The method includes receiving one or more multi-resolution medical images of one or more tissues. Each multi-resolution medical image is divided into a plurality of segments. Thereafter, each segment of the plurality of segments of each multi-resolution medical image is processed in parallel, utilizing one or more computation nodes, wherein each computation node includes one or more Graphical Processing Units (GPUs). The results corresponding to each segment of a multi-resolution medical image are collated, and a collated report is displayed.

Abstract: Provided is a method for imaging a blood sample and a kit and system for executing the method. The method includes introducing a cell suspension including red blood cells onto a base surface of a carrier having a vertical height (H) being greater than or equal to a vertical depth (h) of the cell suspension when on the base carrier, the cell suspension including a cell concentration (C) being determined by a defined function; allowing the cells in the cell suspension to settle on the base surface of the carrier to form a monolayer of cells thereon; and acquiring at least one microscope image of at least a portion of the monolayer of cells; wherein the at least one microscope image is obtained by a microscope set to Depth Of Field that is not more than 20% of the vertical height of the cell suspension settled on the base surface.

Abstract: The invention relates to a method for determining, the sex of at least one embryo in an egg (12), in which the sex of the embryo is determined by means of at least one detection method which is noninvasive at least with regard to the egg (12), wherein at least one oestradiol value which characterizes the concentration of oestradiol in the egg (12) is determined by means of the noninvasive detection method and the sex is determined as a function of the oestradiol value.

Abstract: Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.

Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomolecules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.

Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

Abstract: The current disclosure provides methods for detecting and quantitating the 6-O-methylguanine-DNA methyltransferase protein (MGMT) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed with formaldehyde containing agents/fixatives and may include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and/or paraffin embedded. A protein sample is prepared from the biological sample and the MGMT protein is quantitated in the sample using SRM/MRM mass spectrometry by quantitating one or more fragment peptides.

Abstract: Provided is a composition comprising an analyte bound to a polymer where the analyte is less than about 2000 MW and the polymer further comprises more than one signal or first member of a second binding pair. Also provided is an assay for an analyte comprising combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.

Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.

Abstract: Embodiments described herein relate to assay methods and kits for detecting resistance of any enzyme to its inhibitor due to functional alteration of the enzyme, comprising, conducting two or more reactions with two or more reagent mixes optionally containing substrates for the enzyme. The mixes are substantially similar, except that one contains no enzyme inhibitor whereas the others contain an enzyme inhibitor being tested for resistance. The ratio of the signal from the reaction with an inhibitor to that from a reaction without an inhibitor is used to indicate whether the enzyme is resistant to the enzyme inhibitor and also determine the susceptibility or resistance of the enzyme to various inhibitors and further identify enzyme variants. Embodiments further relate to assay methods comprising only two reactions—one conducted in a mix containing the inhibitor and the other without the inhibitor. Further included are devices for conducting such assays.

Abstract: A mechanism is provided for sequencing a biopolymer. The biopolymer is traversed from a first medium to a second medium. The biopolymer includes bases. As the biopolymer traverses from the first medium to the second medium, different forces are measured corresponding to each of the bases. The bases are distinguished from one another according to the different measured forces which are measured for each of the bases.

Abstract: The present invention provides a category of cyano-substituted asymmetric cyanine dyes having the following general structural Formula I and its synthesizing method. The cyano-substituted asymmetric cyanine dyes in present invention are easily synthesized and have long emission wavelength, high molar extinction coefficient, high sensitivity, good light stability, high fluorescence quantum yield after binding with nucleic acid, and low cell toxicity, which is beneficial for application as fluorescent dyes and could also be used in the field of identifying nucleic acid molecules, clinical diagnostics, and immunoassay testing etc.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: The present invention relates to a screening method for determining whether or not a candidate compound is a modulator of an insect transient receptor potential V (TRPV) channel. The present invention further provides a method of insect control by applying to an insect-specific TRPV channel modulator determined by the screening method. The present invention further relates to an expression vector that includes a nucleic acid molecule coding for an insect TRPV channel. Also, the present invention relates to cell that includes the expression vector encoding a TRPV channel.

Abstract: A method for analyzing a sample using capillary electrophoresis is provided. By the method, following steps are performed. First, an original sample and an anionic group-containing compound are fixed to form a mixed sample, where the original sample contains an analysis component to be analyzed and a sub component other than the analysis component. Then, an aggregate of the sub component and the anionic group-containing compound is removed from the mixed sample. Then, electrophoresis is performed in a capillary tube with respect to a complex in which the analysis component and the anionic group-containing compound are bound to each other, while the mixed sample is continuously supplied.

Abstract: Sample container for holding and transferring a liquid sample and method thereof. The sample container includes an inlet configured to allow a liquid sample to enter a sample container, and an outlet configured to allow one or more droplets of the liquid sample to exit the sample container by one or more acoustic ejections respectively. The inlet and the outlet are in different locations.

Abstract: Disclosed herein are cell lines transformed to express G-Protein Coupled Receptor GPCR22 and uses thereof for identifying guanosine analogs and/or other ligands to the receptor. In particular, techniques for transforming Drosophila Schneider 2 cells and human astrocytoma 1321N1 cell to express GPCR22 are disclosed as well as transformed cells lines. The transformed cell lines of the instant disclosure may be useful in identifying guanosine analogs and functional equivalents thereof.

Abstract: This disclosure generally relates to a method, a system and a kit for diagnosing and treating various disease conditions using the gene expression value in a given sample obtained from a subject. This disclosure further relates to selecting the right set of genes as a portfolio of genes for a particular disease. Providing a set of appropriate portfolio of gene for studying the gene expression values and using the values as a diagnostic tool is also disclosed. The gene expression value is further used for intervention by pharmaceuticals as a prediction model for the treatment of the disease. An individual may have a personalized health card that may store the gene expression value for that particular individual. A system may store the data for portability and integrated view of the individual's medical data for effective diagnosis and treatment.

Abstract: A sampling probe, system and analysis method is disclosed. The sampling probe in one embodiment is constructed of a silicon substrate having a first channel, a second channel, a first tapered tip with an opening, and a second tapered tip with an opening, wherein the first channel extends from the first tapered tip opening to the second tapered tip opening, and wherein the second channel extends from an inlet port to a junction with the first channel.

Abstract: Disclosed herein are compositions of, synthesis methods and methods of use for improved molecularly imprinted polymers useful for extracting target molecule compounds of wine.

Abstract: Provided is a substrate modification method that enables improvement of reproducibility in measurement with use of capillary electrophoresis. The substrate modification method includes immobilizing, to a substrate surface, at least two types of modification groups selected from three types of modification groups that are a type of a modification group having one functional group, a type of a modification group having two to nine functional groups, and a type of a modification group having ten or more functional groups.

Abstract: Disclosed herein are systems and methods for assessing electrically active cell cultures. Optionally, the data can be collected using a microelectrode array (MEA). For example, electrically active cells, such as cardiomyocytes, are cultured such that they are in electrical communication with at least a portion of the electrodes of a well of the MEA. The assessments derived from the disclosed methods may be used to reduce the effects of confounding variables in data obtained from an electrically active cell culture. The methods may also be used to determine a quantitative measure of arrhythmia burden. The methods may also be used to decide if a particular culture or set of data is suitable for inclusion in scientific and characterization studies. Also disclosed is a method of finding the global conduction velocity of an electrically active cell culture.

Abstract: The invention relates to the finding that turnover of DISC1 (Disrupted in schizophrenia 1) is mediated by the F-box-containing protein FBXW7 (F-box/WD repeat-containing protein 7). The sequence within DISC1 that binds to FBXW7 and targets DISC1 for turnover by the ubiquitin-proteasome system is identified. The invention provides antagonists that inhibit this interaction and methods of using these antagonists to decrease DISC1 turnover, for example in treatment of neuropsychiatric disorders, as well as methods of identifying new antagonists.

Abstract: A touch display panel includes a substrate, a first electrode layer, and a second electrode layer. The first and second electrode layers are disposed on the substrate. The second electrode layer electrically connects to the first electrode layer and includes a plurality of sensing electrodes. Each sensing electrode includes a plurality of first conductive lines and a plurality of second conductive lines connected to each other. The first and second conductive lines are respectively arranged along first and second directions, wherein the second direction is different from the first direction. In one of two adjacent sensing electrodes, the outermost first conductive line has at least one first edge and at least one second edge connected to the first edge. The first edge corresponds to one of the second conductive lines of the other one of the two adjacent sensing electrodes, and has a curved shape.

Abstract: A method includes receiving a plurality of design files at a computer-based system, wherein each of the design files is indicative of a respective structural design and a structural value associated with the respective structural design, causing a three-dimensional representation of at least a portion of the structural designs to be displayed to a user, causing a cost value to be displayed to the user for each of the displayed structural designs, receiving a user selection of a first structural design of the displayed structural designs, generating an additive manufacturing file indicative of the first structural design in a predefined format, wherein the predefined format enables the processing of the additive manufacturing file into a physical structure through an additive manufacturing process, and transmitting the selected first structural design in the predefined format.

Abstract: A method and corresponding apparatus are disclosed for analysis of a peptide-containing sample. The sample is prepared by adding isotopically-labeled peptides corresponding to endogenous peptides of interest, and the prepared sample is analyzed by liquid chromatography-mass spectrometry (LCMS). Detection in a high-resolution, accurate mass (HRAM) MS1 spectrum of a precursor ion matching an isotopically-labeled peptide triggers acquisition of an MS/MS spectrum (preferably acquired in an ion trap or other fast mass analyzer) to determine if a product ion is present matching a characteristic product ion (e.g., the y1 ion) of the isotopically-labeled peptide. If the characteristic product ion is present, then a HRAM MS/MS spectrum is acquired for detection and quantitation of the corresponding endogenous peptide.

Abstract: Peptides that have been found to facilitate the delivery of siRNA molecules into cells and to function in siRNA mediated silencing of cellular targets are disclosed. Complexes that include one of the peptides and a cargo molecule are disclosed, wherein the peptide and the cargo molecule are coupled non-covalently. Also disclosed are methods of producing and using the peptides/complexes.

Abstract: The invention relates to an improved cell-free protein synthesis method using a eukaryotic cell lysate in the presence of a caspase inhibitor, to a device for carrying out said method, and to the use of a caspase inhibitor for increasing the protein yield or for increasing the stability of the synthesized proteins in such a cell-free protein synthesis method using a eukaryotic cell lysate. In a preferred embodiment of the invention, the cell-free protein synthesis method is carried out as a continuous method in a device which comprises at least two compartments separated by a dialysis membrane. The translation reaction takes place in at least one first compartment, the reaction compartment, and during the translation reaction i) reactants are diffused from at least one other compartment, the supply and discharge compartment, into the reaction compartment, and ii) reaction byproducts are diffused from the reaction compartment into the supply and discharge compartment by means of the dialysis membrane.

Abstract: The present invention relates in particular to methods of detecting predisposition to or diagnosis and/or prognosis of Charcot-Marie-Tooth disease (CMT) and related disorders. More specifically, the invention relates to development, validation and application of new biomarkers which can be used for detecting the presence or risk of CMT disease and related disorders. In particular, the present invention relates to metabolite, lipid, carbohydrate and proteinaceous biomarkers that can be measured in biological body fluids and easily available extracts of biopsies, which can be used to aid in the detection, prediction of drug treatment and follow-up of this treatment of neurodegenerative disorders, including CMT disease. The present invention also relates to methods for identification of CMT disease subtypes and assessing the responsiveness to treatments and the efficacy of treatments in subjects having CMT or a related disorder.

Abstract: The present invention relates to methods and assays for identifying agents capable of modulating GPR84 activity in cells, in particular agents that inhibit GPR84-agonist stimulated chemotaxis. Inhibition of GPR84-agonist stimulated chemotaxis is useful in the prevention and/or treatment of inflammatory conditions. In particular, the present invention provides methods and assays for identifying agents for use in the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF)), neuroinflammatory conditions, infectious diseases, autoimmune diseases and/or diseases involving impairment of immune cell functions.